ResearcherWest Virginia UniversityActive in the last 2 years
Midhun Malla
Matched on ORCID iD 0000-0002-9969-588X; OpenAlex author ID A5056209015. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 35
2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers
Papers 6
- Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-026-12810-2↗
- ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment Co-author DOI 10.64898/2026.01.15.699725↗
- Emerging therapeutic advancements in pancreatic cancer: a contemporary review. Co-author DOI 10.1007/s12672-025-03027-8↗
- Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae155↗
- Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Time for a Personalized Approach? First author DOI 10.1097/mpa.0000000000002147↗
- The evolving role of radiation in pancreatic cancer. Co-author DOI 10.3389/fonc.2022.1060885↗
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mehmet Akce · 3 shared papers, 2025–2026 · strength 0.83
- Paper Emerging therapeutic advancements in pancreatic cancer: a contemporary review. DOI 10.1007/s12672-025-03027-8↗
- Paper ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment DOI 10.64898/2026.01.15.699725↗
- Paper Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancrea… DOI 10.1007/s00330-026-12810-2↗
- Bassel F. El‐Rayes · 3 shared papers, 2025–2026 · strength 0.83
- Paper Emerging therapeutic advancements in pancreatic cancer: a contemporary review. DOI 10.1007/s12672-025-03027-8↗
- Paper ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment DOI 10.64898/2026.01.15.699725↗
- Paper Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancrea… DOI 10.1007/s00330-026-12810-2↗
- Harrison Kim · 2 shared papers, 2026 · strength 0.51
- Paper ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment DOI 10.64898/2026.01.15.699725↗
- Paper Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancrea… DOI 10.1007/s00330-026-12810-2↗
- Ashiq Masood · 1 shared paper, 2026 · strength 0.27
- Sujith Sarvesh · 1 shared paper, 2026 · strength 0.27
- Dhana Sekhar Reddy Bandi · 1 shared paper, 2026 · strength 0.27
- Karina Jin Yoon · 1 shared paper, 2026 · strength 0.27
- Ganji Purnachandra Nagaraju · 1 shared paper, 2026 · strength 0.27
- Jeremy B. Foote · 1 shared paper, 2026 · strength 0.27
- Zhi-Ren Liu · 1 shared paper, 2026 · strength 0.27
- Amanda Puleo · 1 shared paper, 2022 · strength 0.26
- Brian A. Boone · 1 shared paper, 2022 · strength 0.26
- Martin D. Holland · 1 shared paper, 2026 · strength 0.24
- John Bart Rose · 1 shared paper, 2026 · strength 0.24
- Moh'd M. Khushman · 1 shared paper, 2026 · strength 0.24
- Desiree E. Morgan · 1 shared paper, 2026 · strength 0.24
- Dana Backlund Cardin · 1 shared paper, 2026 · strength 0.24
- Sushanth Reddy · 1 shared paper, 2026 · strength 0.24
- Hassan A. Hatoum · 1 shared paper, 2022 · strength 0.17
- Nadia Karen Malik · 1 shared paper, 2022 · strength 0.17
- Richard M. Goldberg · 1 shared paper, 2022 · strength 0.17
- Sarbajit Mukherjee · 1 shared paper, 2022 · strength 0.17
- Sreenivasa Rao Chandana · 1 shared paper, 2024 · strength 0.15
- Naomi H. Fei · 1 shared paper, 2024 · strength 0.15
- Abdullah Esmail · 1 shared paper, 2024 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.